DeepLife

French tech company | Builders Republic

About

Drug-discovery company that builds AI-driven digital twins of human cells to speed up therapeutic research for biopharma — its Cell Blueprint platform combines large multi-omics datasets, systems biology and generative AI to map cellular networks and pinpoint targets, with focus on autoimmune and neurodegenerative diseases.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Series A
Founded
2019
City
VERNON
Region
IDF
Tracked rounds
2
Amount raised
16 M€ raised since 2020

Funding rounds

  • Series A — 2024
  • Series A — 2022

Investors